Imexpharm Corp (VN:IMP) — Market Cap & Net Worth
Market Cap & Net Worth: Imexpharm Corp (IMP)
Imexpharm Corp (VN:IMP) has a market capitalization of $205.38 Million (₫5.41 Trillion) as of August 1, 2026. Listed on the VN stock exchange, this Vietnam-based company holds position #16389 globally and #91 in its home market, demonstrating a 0.29% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Imexpharm Corp's stock price ₫35100.00 by its total outstanding shares 154008962 (154.01 Million). See Imexpharm Corp (IMP) reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Imexpharm Corp Market Cap History: 2015 to 2026
Imexpharm Corp's market capitalization history from 2015 to 2026. Data shows growth from $43.64 Million to $205.38 Million (14.49% CAGR).
Imexpharm Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Imexpharm Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Imexpharm Corp's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.00x
Imexpharm Corp's market cap is 0.00 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $82.49 Million | $1.40 Trillion | $162.39 Billion | 0.00x | 0.00x |
| 2020 | $128.60 Million | $1.37 Trillion | $209.70 Billion | 0.00x | 0.00x |
| 2021 | $181.11 Million | $1.27 Trillion | $189.09 Billion | 0.00x | 0.00x |
| 2022 | $143.34 Million | $1.64 Trillion | $223.54 Billion | 0.00x | 0.00x |
| 2023 | $148.51 Million | $1.99 Trillion | $299.56 Billion | 0.00x | 0.00x |
| 2024 | $275.02 Million | $2.21 Trillion | $320.86 Billion | 0.00x | 0.00x |
| 2025 | $307.20 Million | $2.44 Trillion | $349.14 Billion | 0.00x | 0.00x |
Competitor Companies of IMP by Market Capitalization
Companies near Imexpharm Corp in the global market cap rankings as of August 1, 2026.
Key companies related to Imexpharm Corp by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #503 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #528 globally with a market cap of $50.48 Billion USD ( CN¥344.98 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #550 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #503 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #528 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.48 Billion | CN¥54.08 |
| #550 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.60 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €15.50 |
Imexpharm Corp Historical Marketcap From 2015 to 2026
Between 2015 and today, Imexpharm Corp's market cap moved from $43.64 Million to $ 205.38 Million, with a yearly change of 14.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₫205.38 Million | -33.14% |
| 2025 | ₫307.20 Million | +11.70% |
| 2024 | ₫275.02 Million | +85.18% |
| 2023 | ₫148.51 Million | +3.61% |
| 2022 | ₫143.34 Million | -20.86% |
| 2021 | ₫181.11 Million | +40.83% |
| 2020 | ₫128.60 Million | +55.90% |
| 2019 | ₫82.49 Million | -17.90% |
| 2018 | ₫100.47 Million | +6.11% |
| 2017 | ₫94.68 Million | +32.75% |
| 2016 | ₫71.33 Million | +63.45% |
| 2015 | ₫43.64 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Imexpharm Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $205.38 Million USD |
| MoneyControl | $205.38 Million USD |
| MarketWatch | $205.38 Million USD |
| marketcap.company | $205.38 Million USD |
| Reuters | $205.38 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Imexpharm Corp
Imexpharm Corporation operates as a pharmaceutical company in Vietnam. The company's products include injectable antibiotics, oral antibiotics, cardiovascular, ophthalmology, musculoskeletal system, analgesic - anti-inflammatory - antipyretics, respiratory system, antihistamines and anti-allergy, central nervous system, digestive system, diabetes, anti-parasitic, external drugs, vitamins and mine… Read more